ReviewFrontiers in microbiology2026
The gut-heart axis in heart failure: from bidirectional pathophysiological mechanisms to integrative therapeutic strategies.
Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanisms of gut microbiota metabolite-mediated gut-heart Axis in heart failure: An integrative study based on network pharmacology.American heart journal plus : cardiology research and practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF), as the terminal stage of cardiovascular diseases, involves complex pathophysiological mechanisms that extend beyond the heart itself and involve the interactive regulation of multiple organ systems. The gut-heart axis theory reveals that the gut microbiota, functioning as a micro-organ, plays a core role in the development and progression of HF through bidirectional regulatory mechanisms. HF-induced hemodynamic disturbances reshape the gut microenvironment, leading to the collapse of intestinal physical and immune barrier functions. In this altered microenvironment, dysregulated gut bacteria release excessive pro-inflammatory metabolites while reducing protective signaling molecules, thereby activating inflammatory pathways including Toll-Like Receptor 4/Nuclear Factor-κB and NOD-like receptor protein 3 inflammasomes. Traditional Chinese medicine (TCM) is the most import integrative medicine to treat HF, and the combination of TCM and western medicine have reached certain progress. This article aims to describe the pathological feedback mechanism between HF and gut microbiota, as long as summary how TCM and western medicine treat HF through regulate gut-heart axis. In specific, modern medicine optimizes hemodynamics to improve the macroscopic microenvironment, thereby establishing a foundation for gut microbiota remodeling. TCM exerts holistic regulatory advantages through multiple components and targets, inhibiting the production of gut-derived inflammatory factors at their source by reshaping the oxygen gradient, providing prebiotic substrates, and repairing intestinal barrier integrity. These could provide a theoretical basis and research reference for precision-oriented HF prevention and management from the perspective of intestinal microecology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.